CliffBio
biologic

Albuked, Plasbumin-20, Plasbumin-25, Plasbumin-5

Albumin (Human)

Loss of exclusivityOctober 1954projected — 12-year biologic exclusivity estimate
CompanyGrifols →See this company's full patent-cliff portfolio

Drug detail

Brand nameAlbuked, Plasbumin-20, Plasbumin-25, Plasbumin-5
Active ingredientAlbumin (Human)
Strength25G/500ML
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 1942
Marketing statusRx

More from Grifols

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Albuked, Plasbumin-20, Plasbumin-25, Plasbumin-5 patent cliff — loss of exclusivity October 1954 | CliffBio